Theraclion SA announced FDA (Food & Drug Administration) approval for the first trial with SONOVEIN in the United States (US). After this clinical trial, a full pivotal study will be conducted for FDA review for market authorisation. The study will be initiated as soon as possible and conducted in a well-known New Jersey Center by Steve Elias MD FACS DABVLM, an internationally recognized vein specialist with more than 30 years experience in the treatment of venous disease. The study will be conducted in collaboration with Dr. Nicos Labropoulos and Dr. Antonios Gasparis both internationally recognized vein specialists with more than 30 years experienced too. It is a crucial milestone for Theraclion to access the largest market for varicose veins with an estimated 2,3 million procedures representing healthcare spending of $5 Billion. It has historically been under penetrated but will expand with the development of painless and non-invasive technologies such as SONOVEIN.